Table 2.

Activity	Compound	Clinical trial
Inhibitors of Tau hyperphosphorylation: glycogen synthase kinase 3 inhibitors (GSK3β)	(i) Tideglusib (ii) NP031112 (iii) Sodium selenite (VEL015)	(i) NCT01350362 phase II (ii) NCT00948259  (iii) ACTRN12611001200976 phase II
Inhibitors of Tau aggregation	RemberTM, TRx 0237	NCT01626391, NCT01689233, NCT01689246 and NCT01626378
Microtubule stabilizers	(i) Paclitaxel (ii) Epothilone D (iii) TPI 287 (taxane)	(i) Clinical trial 2013 (interrupted) (ii) NCT01966666
Tau-specific immunotherapy	AADvac1 vaccine	NCT01850238 and NCT02031198 phase I trial (2013)
Anticholinesterase inhibitors	(i) Donepezil, rivastigmine, galantamine, (ii) Ladostigil (TV3326)
PrPC–mGluR5–Fyn signaling	(i) Masitinib (ii) Saracatinib (AZD0530)	(i) NCT00976118  (ii) NCT01864655 and NCT02167256
5-HT6 receptor blockage	Lu-AE-58054 (SGS-518), PF-05212365 (SAM-531), SUVN-502, AVN-322, PRX-07034	Different phases of clinical trials
Antidiabetic drugs	(i) Rosiglitazone and pioglitazone (ii) Intranasal insulin (Humulin R U-100) (iii) Amylin and pramlintide (amylin analog)	(i) NCT00550420, NCT00348140 phase III (ii) NCT01767909  (iii) NCT01429623 and NCT01354691 phase II
Cdk5 inhibitors	Roscovitine and flavopiridol